Researchers suggest short transition period....

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Researchers suggest short transition period....

Post by MSUK » Thu Jun 18, 2015 2:46 am

Researchers suggest short transition period between RRMS therapies

A team led by researchers at the University Hospital Basel in Switzerland say they have found a short period of eight to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from Tysabri (natalizumab) to Gilenya (fingolimod) therapy.... Read More - http://www.ms-uk.org/gilenya
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post